Biomarkers are important tools for diagnosing cancer and disease in patients, prescribing treatment and monitoring outcomes, and include the following main types.
Figure 1. Schematic diagram of whole genome sequencing, whole exome sequencing, and target region sequencing comparison.
CD Genomics supports its customers in biomarker discovery research by providing NGS-based whole genome sequencing, whole exome sequencing and target region capture sequencing. Whole genome sequencing allows for the determination of all genes in the genome, as well as the simultaneous detection of exons, introns and regulatory sequences. In contrast, exome sequencing mainly detects exon sequences that make up 1% of the genome, but the detection depth is deeper and more cost-effective. Because the majority of disease-causing genes are currently located in the exons of the human genome, exome sequencing can meet the needs of most disease detection. Targeted region capture enables region-specific sequencing, and our experienced experts can assist you with a range of customized needs.
CD Genomics is committed to advancing the discovery of disease biomarkers through efficient genome sequencing, thereby accelerating the development of relevant drugs and personalized therapies. For biomarker discovery, you can choose the sequencing service you need at CD Genomics according to your needs. Our experienced team of experts are involved throughout the process to provide you with relevant consulting services and sequencing advice.
Whole genome sequencing (WGS) provides a complete analysis of the entire genome DNA sequence, including DNA in the nucleus, chloroplasts and mitochondria. whole genome sequencing has broad coverage and can analyze the full range of genetic data at the individual or population level. CD Genomics offers you high-throughput and accurate NGS-based whole genome sequencing services. Each step is performed by our experienced experts under strict quality control and procedural settings to ensure accurate and reliable data results for you.
Exome sequencing is cost-effective and efficient because exome sequences cover almost 85% of common disease genes. CD Genomics can provide you with NGS-based whole exome sequencing services to support you in performing more in-depth biomarker analysis related to genetic information. We are committed to inspiring your ideas for biomarker research through our high depth and sensitivity exome sequencing services. CD Genomics-based offers a one-stop exome sequencing service, so you only need to provide test samples and will receive a comprehensive or customized bioinformatics analysis report in the shortest turnaround time.
CD Genomics has been committed to providing NGS-based targeted region sequencing services to assist you in the development of biomarkers and subsequent targeted and drug development studies. Our high-sensitivity targeted sequencing services provide more comprehensive, detailed and reliable data analysis results while maintaining high efficiency. Targeted region sequencing is designed to help you obtain region-specific information such as point mutations, insertions or deletions (InDels), copy number variants (CNVs) and gene rearrangements, offering greater freedom and selectivity than whole genome sequencing and whole exome sequencing.
We are convinced that CD Genomics is the partner you have been seeking for your biomarker discovery. Our automated sequencing platform and dedicated team of experts guarantee the accuracy of sequencing and analysis results. If you are interested in the biomarker discovery solutions offered by CD Genomics, please feel free to contact us.
CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.
